Since 2009, a dozen of excellent review articles has provided comprehensive analyses of drug related toxicities from some 90 phase I–II monotherapy cancer clinical trials with several generations of Hsp90 ATP-binding inhibitors.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 The maximum tolerable dose (MTD) of the inhibitors was determined based on pharmacodynamic (PD) studies limited to liver toxicity and client protein measurements from isolated PBMC. The gene discussed is HSP90AA1; the disease is cancer.